Page 74 - NPPA full book

MEETING THE EMERGING CHALLENGES OF

RISING NON-COMMUNICABLE DISEASES (NCDS)

To ensure availability of high quality
hile playing a significant role in mee ng the requirements of the drugs globally, Indian pharma companies have
medicines at low prices, thousands of Jan
been able to address domes c needs too. They are fully equipped to address the new, emerging challenges of
Aushadhi Kendras have been opened across the
WNon-communicable diseases (NCDs). NCDs are caused by a combina on of gene c, environmental, and lifestyle
country, where medicines are being sold at 50% -
factors and include heart disease, cancer, diabetes, and respiratory diseases. The mortality rates due to communicable,
90% cheaper rates compared to market rates.
maternal, neonatal, and nutri onal diseases decreased by 63% between 1990 and 2019, while the mortality rate due to NCDs
These have greatly benefited not only the poor
increased by 47% during the same period. NCDs are now the leading cause of death in India and accounts for about 62% of all
but also the middle class.
deaths. The burden of NCDs in India has been increasing over the years which accounts for 55% of the total disability-adjusted
life years (DALY) lost. The burden of NCDs can be reduced by implemen ng effec ve preven ve measures and improving
Narendra Modi
access to quality healthcare. Promo ng healthy lifestyles such as regular exercise, a balanced diet, and reducing tobacco and
Prime Minister of India
alcohol consump on can significantly reduce the risk of NCDs.

Women empowerment is also a direct outcome of this scheme. To ensure easy availability of the menstrual health services to all Indian Pharma companies are aware of the challenge of NCDs and are

women across the country, “Jan Aushadhi Suvidha Oxy-Biodegradable Sanitary Napkin” is available for sale in all PMBJP commi ed to addressing it through innova ve solu ons including drug

Kendras across the country at Rs 1.00 (US$ 0.012 approx) per sanitary pad. Till June, 2023, more than 400 million pads have therapy, crea on of an en re ecosystem around pa ents with lifestyle
been sold through these outlets. modifica ons, nutri on, and pa ent access programs. Their focus on

outcomes and pa ent-centric approaches has led to the introduc on of
A Satisfactory Outcome
the latest medica ons at affordable prices, which is crucial given that

In 2022-23 fiscal, Pharmaceu cals & Medical Devices Bureau of India (PMBI) had made sales of Rs. 1236 crore (over US$ 150 most Indian pa ents pay out of pocket.

million approx). This resulted in saving about Rs. 7400 crore (US$902 million approx) to the Indian ci zens and amplified the
pharmaceu cal industry’s growth. Approximately Rs. 20,000 crore (US$ 2.4 billion approx) have been saved under this scheme

in the last 9 years.

Mr. Samir Mehta, Chairman

Torrent Pharmaceu cals Limited

64 65